NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

April 29, 2019

Study Completion Date

July 8, 2019

Conditions

Psoriasis VulgarisPlaque Psoriasis

Interventions

DRUG

PRCL-02

Oral tablets

DRUG

Placebo

Oral tablets

Trial Locations (16)

69063

Zaporizhzhya Regional Dermatovenereology Clinical Hospital, Zaporizhzhya

R3M3Z4

Wiseman Dermatology Research Inc., Winnipeg

L4M 7G1

SimcoDerm Medical and Surgical Dermatology, Barrie

N6H5L5

DermEffects, London

L3P1X2

Lynderm Research Inc., Markham

K9J5K2

SKiN Centre for Dermatology, Peterborough

N2J1C4

K. Papp Clinical Research, Waterloo

H3Z2S6

Carey-Wang - Dermatology & Dermatologic Surgery Center, Westmount

085 01

Maxderm Dermatovenerologická ambulancia, Bardejov

831 03

SKINKLINIK Dermatovenerologická ambulancia, Bratislava

841 02

BeneDerma, Bratislava

851 01

Derma therapy, spol., Bratislava

949 01

AHS Dermatology, Nitra

089 01

SANARE - Dermatovenerologická ambulancia, Svidník

01601

Oleksandrivska Clinical Hospital, Department of Dermatology and Venereology, Kiev

04050

LLC MK BLAGOMED, Department of Dermatology, Kyiv